Zubic Lifescience Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 3.35 Cr
as on 17-07-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 25.60 Cr
as on 17-07-2024
- Revenue %
(FY 2018)
- Profit 8.65%
(FY 2018)
- Ebitda 8.65%
(FY 2018)
- Net Worth -0.54%
(FY 2018)
- Total Assets 20.59%
(FY 2018)
About Zubic Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 3.35 Cr.
The company currently has active open charges totaling ₹25.60 Cr.
Rameshbhai Vekaria, Hareshkumar Dodia, Paraskumar Kachhadiya, and Five other members serve as directors at the Company.
- CIN/LLPIN
U24233GJ2015PTC082622
- Company No.
082622
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Mar 2015
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodaraa, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Zubic Lifescience?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hareshkumar Dodia  | Additional Director | Current | |
| Rameshbhai Vekaria | Additional Director | Current | |
| Paraskumar Kachhadiya | Director | 18-Mar-2015 | Current |
| Mehul Kachhadiya | Director | 18-Mar-2015 | Current |
| Mukeshbhai Poshia | Director | 18-Mar-2015 | Current |
| Nilesh Poshia | Director | 18-Mar-2015 | Current |
Financial Performance of Zubic Lifescience.
Zubic Lifescience Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 8.65% increase in profit. The company's net worth dipped by a decrease of 0.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zubic Lifescience?
In 2018, Zubic Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Manas Clinical Research Private LimitedActive 13 years 6 monthsHareshkumar Dodia is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 May 2016 | ₹12.80 Cr | Open |
Others Creation Date: 13 May 2016 | ₹12.80 Cr | Open |
How Many Employees Work at Zubic Lifescience?
Unlock and access historical data on people associated with Zubic Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zubic Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zubic Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
